Experimental CAR-T cells targeting HER2 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a cancer that has spread to nearby lymph nodes or other parts of the body and surgery alone cannot cure it.
- You are well enough to do most of your daily activities without help (fully active or only limited in strenuous activity).
- Your cancer can be seen on scans (measurable disease) and you are expected to live at least 3 more months.
- You have not received CAR-T cell therapy or any similar cell-based treatment before.
- Your cancer has not spread to the brain or spinal cord, and you do not have a history of certain serious heart, lung, or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.